These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34095318)

  • 21. [MiR-34a alleviates podocyte injury in mice with diabetic nephropathy by targeted downregulation of Notch signaling pathway].
    Wang H; Liu H; Zhang Y; Chen W
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1839-1845. PubMed ID: 36651252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitamin D down-regulates TRPC6 expression in podocyte injury and proteinuric glomerular disease.
    Sonneveld R; Ferrè S; Hoenderop JG; Dijkman HB; Berden JH; Bindels RJ; Wetzels JF; van der Vlag J; Nijenhuis T
    Am J Pathol; 2013 Apr; 182(4):1196-204. PubMed ID: 23385000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective effects of tacrolimus on podocytes in early diabetic nephropathy in rats.
    Peng T; Chang X; Wang J; Zhen J; Yang X; Hu Z
    Mol Med Rep; 2017 May; 15(5):3172-3178. PubMed ID: 28339051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy.
    Tian N; Gao Y; Wang X; Wu X; Zou D; Zhu Z; Han Z; Wang T; Shi Y
    Drug Des Devel Ther; 2018; 12():2195-2211. PubMed ID: 30034224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin reduces TRPC6 expression through AMPK activation and modulates cytoskeleton dynamics in podocytes under diabetic conditions.
    Szrejder M; Rachubik P; Rogacka D; Audzeyenka I; Rychłowski M; Kreft E; Angielski S; Piwkowska A
    Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165610. PubMed ID: 31778750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases.
    Ilatovskaya DV; Staruschenko A
    Am J Physiol Renal Physiol; 2015 Sep; 309(5):F393-7. PubMed ID: 26084930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury.
    Verheijden KAT; Sonneveld R; Bakker-van Bebber M; Wetzels JFM; van der Vlag J; Nijenhuis T
    J Am Soc Nephrol; 2018 Aug; 29(8):2099-2109. PubMed ID: 29954830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sirt6 ameliorates high glucose-induced podocyte cytoskeleton remodeling via the PI3K/AKT signaling pathway.
    Zhang Z; Huang H; Tao Y; Liu H; Fan Y
    Ren Fail; 2024 Dec; 46(2):2410396. PubMed ID: 39378103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Astragaloside IV protects against podocyte apoptosis by inhibiting oxidative stress via activating PPARγ-Klotho-FoxO1 axis in diabetic nephropathy.
    Xing L; Fang J; Zhu B; Wang L; Chen J; Wang Y; Huang J; Wang H; Yao X
    Life Sci; 2021 Mar; 269():119068. PubMed ID: 33476631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetrandrine Attenuates Podocyte Injury by Inhibiting TRPC6-Mediated RhoA/ROCK1 Pathway.
    Mao L; Ding Y; Yu D; Yin J; Yu J
    Anal Cell Pathol (Amst); 2022; 2022():7534181. PubMed ID: 36247873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient receptor potential channel 6 (TRPC6) protects podocytes during complement-mediated glomerular disease.
    Kistler AD; Singh G; Altintas MM; Yu H; Fernandez IC; Gu C; Wilson C; Srivastava SK; Dietrich A; Walz K; Kerjaschki D; Ruiz P; Dryer S; Sever S; Dinda AK; Faul C; Reiser J
    J Biol Chem; 2013 Dec; 288(51):36598-609. PubMed ID: 24194522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protease-Activated Receptor 1-Mediated Damage of Podocytes in Diabetic Nephropathy.
    Bohovyk R; Khedr S; Levchenko V; Stefanenko M; Semenikhina M; Kravtsova O; Isaeva E; Geurts AM; Klemens CA; Palygin O; Staruschenko A
    Diabetes; 2023 Dec; 72(12):1795-1808. PubMed ID: 37722138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Podocyte injury in diabetic nephropathy: implications of angiotensin II-dependent activation of TRPC channels.
    Ilatovskaya DV; Levchenko V; Lowing A; Shuyskiy LS; Palygin O; Staruschenko A
    Sci Rep; 2015 Dec; 5():17637. PubMed ID: 26656101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease.
    Kang JS; Lee SJ; Lee JH; Kim JH; Son SS; Cha SK; Lee ES; Chung CH; Lee EY
    Sci Rep; 2019 May; 9(1):7679. PubMed ID: 31118506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Swiprosin-1 Promotes Mitochondria-Dependent Apoptosis of Glomerular Podocytes via P38 MAPK Pathway in Early-Stage Diabetic Nephropathy.
    Wang RM; Wang ZB; Wang Y; Liu WY; Li Y; Tong LC; Zhang S; Su DF; Cao YB; Li L; Zhang LC
    Cell Physiol Biochem; 2018; 45(3):899-916. PubMed ID: 29421811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of siRNA-silenced TRPC6 on podocyte autophagy and apoptosis induced by AngII.
    Shengyou Y; Li Y
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1266-73. PubMed ID: 25143325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hirudin Protects Against Kidney Damage in Streptozotocin-Induced Diabetic Nephropathy Rats by Inhibiting Inflammation via P38 MAPK/NF-κB Pathway.
    Han J; Pang X; Zhang Y; Peng Z; Shi X; Xing Y
    Drug Des Devel Ther; 2020; 14():3223-3234. PubMed ID: 32848363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tripterygium glycoside protects diabetic kidney disease mouse serum-induced podocyte injury by upregulating autophagy and downregulating β-arrestin-1.
    Zhan H; Jin J; Liang S; Zhao L; Gong J; He Q
    Histol Histopathol; 2019 Aug; 34(8):943-952. PubMed ID: 30839094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Participation of the AngII/TRPC6/NFAT axis in the pathogenesis of podocyte injury in rats with type 2 diabetes.
    Ma R; Xu Y; Zhou H; Zhang D; Yao D; Song L; Liu Y
    Mol Med Rep; 2019 Mar; 19(3):2421-2430. PubMed ID: 30664212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity.
    Hall G; Rowell J; Farinelli F; Gbadegesin RA; Lavin P; Wu G; Homstad A; Malone A; Lindsey T; Jiang R; Spurney R; Tomaselli GF; Kass DA; Winn MP
    Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1442-50. PubMed ID: 24740790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.